News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.

1Bitget UEX Daily|Gold and Silver Turn Positive After Volatility; Huang Renxun Clarifies OpenAI Investment; SpaceX Applies for Million Satellites (February 2, 2026)2Bitcoin Plunge Could Get Much Worse as Death Cross Gains Power3 Crypto Market Today Turns Red But LTH Data Signals Structural Stability
Revolutionary: MoneyGram’s New Stablecoin Payments System with Fireblocks Changes Everything
BitcoinWorld·2025/12/04 18:09
BTC Price Soars: Bitcoin’s Stunning Rally Breaks $93,000 Barrier
BitcoinWorld·2025/12/04 18:09
Metaverse Budget Shock: Meta Considers Slashing 30% from Reality Labs
BitcoinWorld·2025/12/04 18:09
Bitcoin Price Plummets: BTC Falls Below $92,000 in Market Shakeup
BitcoinWorld·2025/12/04 18:09

Ripple CEO Projects Bitcoin Could Reach $180,000 by End of 2026
DeFi Planet·2025/12/04 18:03

Solana Mobile Launches SKR Token to Power Seeker Ecosystem Security
DeFi Planet·2025/12/04 18:03

BlackRock’s Larry Fink Admits Bitcoin Misjudgment, Cites $70B ETF Success as Proof
DeFi Planet·2025/12/04 18:03

Ethereum Fusaka Upgrade Goes Live, Boosting Scalability Toward Instant Transactions
DeFi Planet·2025/12/04 18:03

Fanatics Launches Fanatics Markets, Boosting Crypto Prediction Access Nationwide
DeFi Planet·2025/12/04 18:03

Charles Schwab Eyes $12 Trillion Institutional Base with New Crypto ETF Push
DeFi Planet·2025/12/04 18:03
Flash
00:51
WuXi Biologics and Vertex reach licensing and research service agreement for innovative trispecific T-cell engagerGelonghui, February 3rd|WuXi Biologics announced that it has signed a licensing and research services agreement with Vertex Pharmaceuticals (NASDAQ: VRTX) for an innovative trispecific T-cell engager (TCE). Vertex plans to use it for the treatment of B cell-mediated autoimmune diseases. Under the terms of the agreement, Vertex will obtain global exclusive rights for the development and commercialization of this preclinical-stage trispecific TCE intended for the treatment of B cell-mediated autoimmune diseases. WuXi Biologics will receive an upfront payment and is eligible to receive milestone payments related to development, registration, and sales, as well as royalties on product sales after launch. In addition, WuXi Biologics will provide integrated contract research and development services for its innovative TCE.
00:47
「Abraxas Capital」 Takes Profit on HYPE Short, Position Size Reduced to $6.79 MillionBlockBeats News, February 3rd, according to monitoring, the "Abraxas Capital main address" (0x5b5d...) executed a take-profit operation on its HYPE short position, reducing 62,511.35 HYPE, equivalent to about $2.14 million
After this operation, the total value of its HYPE short position dropped to $6.79 million. The position is currently floating a profit of about $1.64 million, with an average holding price of $42.
This address is the main contract address of the well-known hedge fund Abraxas Capital, which has been building up a large short position since May and has once been the largest contract whale on Hyperliquid in terms of funds. Since November, the address has been consistently taking profit, reducing its position size significantly from a peak of $920 million.
00:34
As the market stabilizes, South Korea's Kospi Index rebounds from heavy sell-offGlonghui, February 3rd|The Kospi index once rose by 4.1%, rebounding from Monday's plunge, boosted by technology stocks. Precious metals also rebounded in early trading. Overnight, US stocks rose, with strong manufacturing data helping to lift market sentiment, while concerns over artificial intelligence spending eased. Samsung Electronics and SK Hynix were the biggest contributors to Tuesday's rise in South Korea's Kospi index. Out of 19 sector indices, 18 rose, with the electrical and electronics sector index leading the gains, rising as much as 6%. Retail investors were net buyers of Kospi constituent stocks, while domestic and foreign funds were net sellers. The small-cap Kosdaq index once rose by 3.4%.
News